Enanta Pharmaceuticals | ENTA - Trade Debtors


Enanta Pharmaceuticals reported $40.16M in Trade Debtors for its fiscal quarter ending in December of 2024.





Trade Debtors Change Date
AbbVie USD 12.48B 110M Mar/2026
Amgen USD 10.23B 1.09B Jun/2026
Anika Therapeutics USD 29.33M 661K Dec/2025
Arrowhead Research USD 8.56M 7.13M Jun/2026
AstraZeneca USD 18.86B 972M Jun/2026
BioCryst Pharmaceuticals USD 110.76M 3.94M Jun/2026
Biogen USD 1.79B 76.6M Mar/2026
Bristol-Myers Squibb USD 13.83B 535M Jun/2026
Enanta Pharmaceuticals USD 40.16M 1.52M Dec/2024
Gilead Sciences USD 5.06B 314M Jun/2026
GlaxoSmithKline GBP 8.07B 137M Jun/2026
Halozyme Therapeutics USD 453.33M 4.66M Jun/2026
Heron Therapeutics USD 89.59M 8.54M Dec/2025
Immunic USD 333K 156K Dec/2025
Incyte USD 1.13B 73.7M Jun/2026
Insmed USD 215.32M 36.77M Jun/2026
Ionis Pharmaceuticals USD 58.84M 15.16M Jun/2026
J&J USD 19.05B 3.49B Jun/2026
Karyopharm Therapeutics USD 23.36M 2.82M Mar/2026
Ligand Pharmaceuticals USD 54.8M 6.25M Mar/2026
Merck USD 12.21B 435M Mar/2026
Neurocrine Biosciences USD 887M 118.9M Jun/2026
Novartis USD 9.85B 252M Jun/2026
Novavax USD 106.45M 72.27M Dec/2025
Pfizer USD 16.19B 19M Jun/2026
PTC Therapeutics USD 219.92M 38.3M Mar/2026
Roche Holding CHF 13.34B 1.44B Jun/2026
Sarepta Therapeutics USD 393.8M 154.11M Jun/2026
Vertex Pharmaceuticals USD 2.13B 138.2M Jun/2026